South Korean biopharmaceutical company Celltrion Inc announced on Thursday that STEQEYMA (ustekinumab-stba), a biosimilar to STELARA (ustekinumab), has been added to the Costco Member Prescription Program.

The product is offered in both subcutaneous injection and intravenous infusion, and is indicated for the treatment of plaque psoriasis (PsO) and psoriatic arthritis (PsA) in adult and paediatric patients, and Crohn's disease (CD) and ulcerative colitis (UC) in adult patients.

Costco Specialty Pharmacies will manage sales of STEQEYMA in the United States from 1 April 2025 for self-funded employer plans and Costco members who are uninsured and want to pay cash for their STEQEYMA prescription or who have been denied coverage by their insurers.

Celltrion's adalimumab-aaty was previously added to the Costco Member Prescription Program in August 2024.

Francine Galante, Vice President of Market Access at Celltrion USA, said: "We're focused on improving affordability and access to a widely used, high-cost treatment for a variety of inflammatory conditions. The addition of STEQEYMA to the Costco Member Prescription Program together with adalimumab-aaty will help us deliver our commitment to lowering financial barriers and improving access to critical treatments."